血小板减少症及免疫性血小板减少症的发生率、危险因素与疫苗接种关联的范围综述
本文报告了一项范围综述的结果,旨在更新布莱顿合作组织血小板减少症病例定义配套指南。结果显示血小板减少症背景发生率估计为1.6至92.1/10万人年,含麻疹疫苗和腺病毒载体COVID-19疫苗与免疫性血小板减少症风险升高相关,而mRNA和灭活COVID-19疫苗多未发现关联。
要点
- 血小板减少症背景发生率估计为1.6–92.1/10万人年,因研究、地区和年龄而异。
- 含麻疹疫苗和腺病毒载体COVID-19疫苗与ITP风险升高相关。
- mRNA和灭活COVID-19疫苗多未发现与ITP的关联。
核心结论
- 血小板减少症虽罕见但危险因素众多,包括接种含麻疹疫苗。
- 本综述有助于利益相关者评估不同场景下血小板减少症的发生,包括作为免疫接种后不良事件。
研究设计与样本
- 范围综述,于2024年7月进行两次PubMed检索,分别针对背景发生率与非疫苗危险因素、疫苗关联。
主要发现
- 血小板减少症背景发生率估计范围为1.6至92.1/10万人年,取决于研究、地区和年龄范围。
- 非疫苗危险因素包括年龄、性别、遗传、季节、地理、合并症、医源性因素、感染、药物和食物。
- 研究一致发现含麻疹疫苗与ITP风险升高相关,多项研究发现腺病毒载体COVID-19疫苗接种后风险升高。
- 针对其他疫苗(包括mRNA和灭活COVID-19疫苗)的研究大多未发现关联。
临床怎么用
- 临床和公共卫生人员可参考本综述评估不同背景下血小板减少症的发生率及与疫苗接种的潜在关联。
- 在免疫接种后不良事件监测中,可结合背景发生率和危险因素综合判断血小板减少症病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Brighton Collaboration published its standard harmonized case definition for thrombocytopenia in 2007 to facilitate collection of valid and reproducible vaccine safety evidence and enable valid comparisons across studies. A companion guide to this case definition (including background incidence, risk factors, evidence for or against an association with vaccination, medical codes, data collection forms, and algorithms to support level of diagnostic certainty assessment) was initially published in 2021 and updated in 2025 based on a formal scoping review. This article reports the results of this scoping review, summarizing current evidence regarding the background incidence of and risk factors for thrombocytopenia, including immune thrombocytopenia (ITP) and its potential association with vaccination. METHODS: Two PubMed searches were conducted in July 2024: one for background incidence and non-vaccine risk factors, and one for vaccine associations. Search results were screened and relevant data were extracted and added to the corresponding companion guide tables. FINDINGS: Twenty-two articles contributed to the updated summary of background incidence, 36 articles contributed to the updated summary of non-vaccine risk factors, and 93 articles contributed to the updated summary of vaccine associations. Estimates of the background incidence of thrombocytopenia range between 1.6 and 92.1 per 100,000 person-years, depending on the study, region, and age range. Non-vaccine risk factors for thrombocytopenia include age, sex, genetics, season, geography, comorbidities, iatrogenesis, infection, medication, and food. While studies have consistently found an increased risk of ITP with measles-containing vaccines, and multiple studies found an increased risk following adenoviral COVID-19 vaccination, studies of other vaccines (including mRNA and inactivated COVID-19 vaccines) have largely found no association. CONCLUSION: Though rare, thrombocytopenia has many risk factors, including vaccination against measles. This review should be useful to stakeholders attempting to assess the occurrence of thrombocytopenia across a variety of settings, including as an adverse event following immunization.
引用
- Dudley MZ, Ali H, Villaescusa MR, et al. Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review. Vaccine. 2026. PMID: 42691821. doi:10.1016/j.vaccine.2026.129120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。